Tyra Biosciences, Inc. (TYRA) Insider Trading Activity

NASDAQ$10.92
Market Cap
$580.7M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
16 of 863
Rank in Industry
12 of 492

TYRA Insider Trading Activity

TYRA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$35,308,026
8
21
Sells
$8,954,692
30
79

Related Transactions

RA CAPITAL MANAGEMENT, L.P.
7
$35.16M
0
$0
$35.16M
Fuhrman AlanChief Financial Officer
1
$151,954
0
$0
$151,954
KAPLAN GILLAdirector
0
$0
5
$628,263
$-628,263
Harris ToddPresident and CEO
0
$0
12
$3.91M
$-3.91M
Kjellson Nina Sdirector
0
$0
13
$4.41M
$-4.41M

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Insider Activity of Tyra Biosciences, Inc.

Over the last 12 months, insiders at Tyra Biosciences, Inc. have bought $35.31M and sold $8.95M worth of Tyra Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Tyra Biosciences, Inc. have bought $54.29M and sold $8.43M worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $35.16M. Fuhrman Alan (Chief Financial Officer) — $151,954.

The last purchase of 11,813 shares for transaction amount of $119,666 was made by RA CAPITAL MANAGEMENT, L.P. () on 2025‑06‑16.

List of Insider Buy and Sell Transactions, Tyra Biosciences, Inc.

2025-06-18SaleKAPLAN GILLAdirector
9,568
0.0185%
$9.78
$93,596
+3.89%
2025-06-17SaleKAPLAN GILLAdirector
10
<0.0001%
$10.35
$104
+2.50%
2025-06-16SaleKAPLAN GILLAdirector
6,814
0.013%
$10.38
$70,726
-4.26%
2025-06-16PurchaseRA CAPITAL MANAGEMENT, L.P.
11,813
0.022%
$10.13
$119,666
-4.26%
2025-06-13SaleKAPLAN GILLAdirector
15,000
0.0279%
$10.31
$154,583
-5.75%
2025-06-13PurchaseRA CAPITAL MANAGEMENT, L.P.
120,167
0.2214%
$10.20
$1.23M
-5.75%
2025-06-12SaleKAPLAN GILLAdirector
30,000
0.0564%
$10.31
$309,255
-4.45%
2025-06-12PurchaseRA CAPITAL MANAGEMENT, L.P.
31,307
0.0582%
$10.20
$319,331
-4.45%
2025-06-09PurchaseRA CAPITAL MANAGEMENT, L.P.
186,850
0.3495%
$10.19
$1.9M
-2.53%
2025-06-05PurchaseRA CAPITAL MANAGEMENT, L.P.
213,334
0.3967%
$10.04
$2.14M
-1.18%
2025-06-04PurchaseRA CAPITAL MANAGEMENT, L.P.
997,864
1.7642%
$9.63
$9.61M
-1.46%
2025-02-05SaleKjellson Nina Sdirector
5,401
0.0103%
$13.76
$74,324
-25.64%
2025-01-23SaleKjellson Nina Sdirector
4,825
0.0092%
$16.26
$78,466
-36.95%
2025-01-21SaleKjellson Nina Sdirector
3,993
0.0078%
$16.36
$65,336
-35.64%
2025-01-17SaleKjellson Nina Sdirector
13,269
0.0254%
$16.40
$217,613
-36.69%
2025-01-16SaleKjellson Nina Sdirector
7,779
0.0148%
$16.29
$126,697
-36.47%
2024-11-25SaleKjellson Nina Sdirector
5,272
0.0108%
$16.84
$88,773
-33.93%
2024-11-08PurchaseRA CAPITAL MANAGEMENT, L.P.
1.22M
2.3305%
$16.25
$19.84M
-32.53%
2024-11-07SaleKjellson Nina Sdirector
22,091
0.0422%
$17.32
$382,574
-36.56%
2024-11-06SaleKjellson Nina Sdirector
52,491
0.1004%
$17.18
$901,559
-36.45%
Total: 106
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
RA CAPITAL MANAGEMENT, L.P.
10259291
19.2924%
$112.03M80
<0.0001%
Harris ToddPresident and CEO
1355927
2.5498%
$14.81M031
Kjellson Nina Sdirector
443885
0.8347%
$4.85M013
KAPLAN GILLAdirector
28231
0.0531%
$308,282.5205
Fuhrman AlanChief Financial Officer
12849
0.0242%
$140,311.0810
Boxer Capital, LLC10 percent owner
6448359
12.126%
$70.42M20
<0.0001%
MORE ROBERT Jdirector
4080296
7.6729%
$44.56M10
<0.0001%
Alta Partners NextGen Fund II Management, LLC10 percent owner
4080296
7.6729%
$44.56M10
<0.0001%
Cormorant Asset Management, LP
1069932
2.012%
$11.68M10
<0.0001%
Bensen DanielChief Operating Officer
427981
0.8048%
$4.67M041
MVA Investors, LLC10 percent owner
22527
0.0424%
$245,994.8402
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$587,109,125
90
3.17%
$543.13M
$28,907,358
35
41.41%
$628.44M
$24,857,912
21
-35.40%
$542.03M
$6,280,187
19
6.80%
$571.74M
$49,750,490
17
37.19%
$581.55M
$21,945,105
15
-26.51%
$664.29M
$18,455,830
13
24.59%
$582.52M
$133,809,976
13
31.29%
$554M
$92,357,691
12
87.24%
$588.52M
$11,541,901
10
8.07%
$552.35M
$3,073,199
10
16.77%
$524.83M
$94,976,497
10
-10.72%
$649.7M
$91,721,700
9
-13.73%
$538.39M
$1,580,951
9
-14.18%
$661.18M
$94,000,000
7
-20.84%
$530.43M
Tyra Biosciences, Inc.
(TYRA)
$73,280,625
6
-41.09%
$580.7M
$3,200,000
5
-11.36%
$624.06M
$1,746,565
4
-29.05%
$561.91M
$13,900
1
-39.25%
$599.48M

TYRA Institutional Investors: Active Positions

Increased Positions65+54.17%13M+23.86%
Decreased Positions48-40%4M-7.43%
New Positions24New6MNew
Sold Out Positions18Sold Out2MSold Out
Total Postitions137+14.17%64M+16.43%

TYRA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ra Capital Management, L.P.$115,521.0020.07%10.64M+220,681+2.12%2024-12-31
Boxer Capital, Llc$70,029.0012.17%6.45M00%2024-09-30
Canaan Partners Xi Llc$45,010.007.82%4.14M-35,267-0.84%2025-03-31
Alta Partners Management Company, L.P.$44,312.007.7%4.08M+4MNew2024-12-31
Nextech Invest Ltd.$44,047.007.65%4.06M00%2024-12-31
Bvf Inc/Il$42,834.007.44%3.94M-717,000-15.38%2024-12-31
Fmr Llc$33,753.005.86%3.11M-264,880-7.85%2024-12-31
Boxer Capital Management, Llc$22,021.003.83%2.03M+2MNew2024-12-31
Tcg Crossover Management, Llc$21,602.003.75%1.99M00%2024-12-31
Janus Henderson Group Plc$18,965.003.3%1.75M+679,124+63.64%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.